In this paper, we examined whether Alzheimer disease (AD) biomarkers predicted the future onset of driving difficulties amount older adults. To do this, we used data from 104 participants who had completed two or more annual road tests. We examined biomarker levels based on amyloid imaging and cerebrospinal fluid. Our data showed that more abnormal ratios of tau and amyloid proteins in the cerebrospinal fluid predicted a faster time to receive a marginal or fail rating on a driving test. However, the amount of amyloid found in brain imaging did not relate to a faster time to failing a driving test. We will continue looking at this data as we move forward in our longitudinal, ongoing studies. Our hope is that driving performance could be a promising functional outcome in AD medication trials.

For more information: Click here